• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MiMedx Group Inc

    5/23/25 4:15:14 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    DEFA14A 1 d14157ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the registrant ☒

    Filed by a party other than the registrant  ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    MIMEDX GROUP, INC.

    (Name of registrant as specified in its charter)

    Payment of the filing fee (check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11

     

     
     


    LOGO

    Your Vote Counts! MIMEDX GROUP, INC. 2025 Annual Meeting Vote by June 17, 2025 11:59 PM ET MIMEDX GROUP, INC. 1775 WEST OAK COMMONS CT. NE MARIETTA, GA 30062 V74425-P32096 You invested in MIMEDX GROUP, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 18, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    1. Election of Directors Nominees: Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1a. M. Kathleen Behrens, Ph.D. For 1b. Joseph H. Capper For 1c. James L. Bierman For 1d. William A. Hawkins, III For 1e. Cato T. Laurencin, M.D. For 1f. K. Todd Newton For 1g. Tiffany Olson For 1h. Dorothy Puhy For 1i. Martin P. Sutter For 2. Advisory approval of executive compensation. For 3. Ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal For year e ding December 31, 2025. 4. Amendment of 2016 Equity and Cash Incentive Plan. For 5. Advisory vote on frequency of advisory vote on executive compensation. 1 Year NOTE: The proxies will vote in their discretion regarding such other business as may properly come before the meeting or any adjournment or any postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V74426-P32096

    Get the next $MDXG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on MiMedx Group with a new price target

    Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    10/27/23 9:04:53 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

    MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511. Sponsored Lunch SymposiumTitle: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving LandscapeDate: Thursday, September 4, 2025Time: 11:40 – 1:10 p.m. PDTFaculty: Paul Kim, DPM, M

    9/3/25 8:00:37 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Participate in Upcoming Investor Conferences

    MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 3, 2025Fireside Chat (1:35 PM ET): Click here to access Lake Street BIG9 Best Ideas Growth Conference | New York, NYThursday, September 11, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their respective Cantor or Lake Street representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helpin

    8/27/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

    7/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    SEC Filings

    View All

    MiMedx Group Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    9/3/25 8:01:41 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    7/30/25 4:03:53 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by MiMedx Group Inc

    10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)

    7/30/25 4:01:02 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 6% to 188,024 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    7/7/25 5:59:59 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 12,034 shares, decreasing direct ownership by 4% to 295,282 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/26/25 4:48:44 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Newton Todd was granted 28,609 shares, increasing direct ownership by 7% to 412,771 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/23/25 6:46:57 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

    7/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

    MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website

    7/16/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces First Quarter 2025 Operating and Financial Results

    Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

    4/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care